BioNTech Completes Acquisition of Biotheus

Core Viewpoint - BioNTech has completed the acquisition of Biotheus, enhancing its oncology strategy and expanding its capabilities in developing and commercializing novel bispecific antibodies, particularly BNT327, for cancer treatment [1][2][7] Group 1: Acquisition Details - The acquisition of Biotheus was finalized for a total consideration of $800 million, primarily in cash, with additional performance-based payments of up to$150 million contingent on achieving specific milestones [3] - Biotheus will function as a new indirect subsidiary of BioNTech in China, contributing a local research and development hub along with an advanced biologics manufacturing facility [2][7] Group 2: BNT327 Overview - BNT327 is a bispecific antibody that combines PD-L1 checkpoint inhibition and VEGF-A neutralization, aiming to enhance anti-tumor immune responses and counteract the immunosuppressive tumor microenvironment [4] - Over 750 patients have been treated with BNT327 in clinical trials, with ongoing studies evaluating its efficacy as a monotherapy and in combination with other treatments for various solid tumors [5] Group 3: Future Development Plans - BioNTech plans to initiate multiple global clinical trials for BNT327 in 2025, targeting first-line treatments for small cell lung cancer, non-small cell lung cancer, and triple-negative breast cancer [5] - The company aims to position BNT327 as a next-generation immuno-oncology backbone in combination with other therapeutic modalities across a wide range of cancer indications [5][7]